General Info

Spectranetics was one of the first companies in the world to explore the possibility of using photo-ablative lasers to clear occluded arteries. After five years of product development, Spectranetics' technology was first used in a procedure at the Texas Heart Institute in 1989. Since then, the company has been developing, manufacturing and marketing its ultraviolet excimer laser technology to physicians and hospitals worldwide. This leading-edge technology is used in multiple cardiovascular procedures to remove arterial blockages and scar tissue while holding pacemaker and ICD cardiac leads in place. Spectranetics maintains its headquarters in Colorado Springs, Colo. The company's common stock is traded on NASDAQ.